On October 26th, Vator Securities arranged the Vator Securities Life Science Summit, a unique healthcare conference where we present some of the most interesting and innovative growth companies in Sweden, bringing together industry leaders, entrepreneurs and top investors.
The participating companies were BoneSupport, SciBase, BioArctic, Immunovia, Cavis Technologies, ExpreS2ion Biotech, CombiGene, SenzaGen and AlgoDx.
Vator Securities acts as Sole Global Coordinator and Sole Bookrunner in ExpreS2ion Biotechnologies 102 MSEK Rights Issue
ExpreS2ion Biotechnologies is a biotechnology company that develops vaccines based on complex proteins targeting infectious diseases and cancer. The company develops a pipeline of preventive and therapeutic vaccine products while generating revenue by outlicensing the company’s ExpreS2 platform.
The lead candidate targeting COVID-19 is outlicensed to Bavarian Nordic, with positive phase II data announced in February 2022 and phase III initiated during September 2022. ExpreS2ion has a strong pipeline with multiple candidates in pre-clinical phase.read more
Vator Securities acted as Sole Global Coordinator and Sole Bookrunner in Immunovia 202 MSEK Rights Issue
Immunovia is a diagnostics company with the vision to revolutionize blood-based diagnostics and increase the survival rate for patients with cancer. Immunovia has launched the first blood test in the world designed for the early detection of pancreatic cancer, a serious form of cancer with a low survival rate. The low survival rate is explained by the fact that pancreatic cancer is usually detected at a late stage when the tumor has metastasized.
Immunovia has developed IMMray® PanCan-d, which is the first blood-based test specifically developed for the early diagnosis of pancreatic ductal adenocarcinoma (PDAC). Since 2016, Immunovia has conducted several large-scale studies targeting the main pancreatic cancer risk groups. Altogether, the studies have been conducted at around 30 hospitals in the USA and Europe and included several thousand patients. Based on the studies conducted, Immunovia’s assessment is that IMMray® PanCan-d has unmatched clinical performance for the early detection of pancreatic cancer.read more
Vator Securities advises SciBase on 80 MSEK Rights Issue
SciBase Holding is a MedTech company that develops point-of-care instruments for non-invasive detection of atopic dermatitis (eczema), skin cancer and other skin diseases. The products are based on the company’s technology platform that combines artificial intelligence (AI) with Electrical Impedance Spectroscopy (EIS), a technology based on more than 20 years of research at the Karolinska Institute.
SciBase’s products include Nevisense and Nevisense Go and currently the platform is addressing detection of atopic dermatitis (eczema), melanoma and non-melanoma skin cancer. Nevisense is the only product that is approved by the Food and Drug Administration (FDA) for detection of melanoma and is the only instrument in Europe with a Medical Device Regulation (MDR) approval for detection of skin cancer.read more
Vator Securities acted as Sole Global Coordinator and Sole Bookrunner in Trustscale AB’s Private Placement through a primary and secondary equity offering to Priveq
Trustscale AB and its operating subsidiary group Verisec International is a global encryption company with a tech platform used by banks and payment providers. Trustscale offers Payment Security and User Authentication to create trust between banks, payment providers, merchants, and consumers through safe digital transactions.
A global regulatory paradigm shift now disrupts status quo and triggers payment encryption services to transform from today’s on premises, single client, market to a new outsourced, cloud based and globally scalable offering.read more
102 MSEK | Q1 2023
202 MSEK | Q1 2023
80 MSEK | Q1 2023
Private Placement to Priveq | Q4 2022